Flutter Entertainment Advances Share Buyback Program
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Flutter Entertainment PLC ( (FLUT)) just unveiled an update.
Flutter Entertainment PLC announced the acquisition and subsequent cancellation of its ordinary shares as part of a share buyback program. This initiative, which aims to repurchase up to $225 million worth of shares by September 30, 2025, is part of a larger $5 billion buyback plan announced in 2024. The buyback is expected to enhance shareholder value and optimize the company's capital structure.
More about Flutter Entertainment PLC
Flutter Entertainment PLC is a global sports betting and gaming company. It offers a wide range of products and services, including online sports betting, gaming, and entertainment solutions. The company operates in various international markets, focusing on delivering innovative and engaging experiences to its customers.
For an in-depth examination of FLUT stock, go to TipRanks' Overview page.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Redwire Launches New Venture Company, SpaceMD, to Commercialize Pharmaceutical Development in Space; Signs Trailblazing Royalty Agreement with ExesaLibero Pharma
Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals. SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire's innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics. As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. The results of these microgravity investigations will inform ExesaLibero Pharma's Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products. 'Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,' said Peter Cannito, Chairman and CEO of Redwire. 'This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.' 'We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,' said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. 'This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.' Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire's microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes. About Redwire Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotech, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.
Globe and Mail
an hour ago
- Globe and Mail
Is Costco Stock Still the Safest Bet? Data Backs the Defensive Case
At a time when volatility continues to haunt, Costco Wholesale Corporation COST remains a poster child for defensive investing. The company's unique membership-based model and pricing discipline have solidified its position as a resilient force in the retail space. A key indicator of this strength is the 90.2% global membership renewal rate, alongside a 5.2% increase in worldwide shopping traffic during the third quarter of fiscal 2025. Membership revenues continue to be a key pillar for Costco. In the third quarter, income from membership fees increased 10.4% year over year, providing a steady revenue stream in a volatile environment. Paid memberships grew 6.8% to 79.6 million, with renewal rates remaining steady at 92.7% in the United States and Canada. Executive memberships, which now account for 73.1% of total sales, demonstrate member loyalty. Costco's operational agility further bolsters its defensive profile. The company has effectively navigated tariff disruptions and supply-chain constraints by rerouting goods and sourcing more from local suppliers. This flexibility helps contain cost pressures and allows it to offer the best possible prices. For example, by manufacturing or procuring Kirkland Signature items within the countries where they are sold, Costco has reduced shipping expenses and improved price consistency. Kirkland Signature continues to gain traction, with its sales outpacing overall company growth and penetration up 50 basis points year over year. Additionally, initiatives like the 'Buy Now, Pay Later' option and e-commerce expansion reflect Costco's forward-thinking approach, strengthening its defensive appeal in an evolving retail landscape. Costco's Price Performance, Valuation and Estimates Costco, which competes with Dollar General Corporation DG and Target Corporation TGT, has been a standout performer, with shares rallying 18.8% in the past year, outpacing the industry 's growth of 11.9%. Shares of Dollar General and Target have declined 11.7% and 25.5%, respectively, in the aforementioned period. From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 48.15, higher than the industry's ratio of 31.77. COST carries a Value Score of D. Costco is trading at a premium to Target (with a forward 12-month P/E ratio of 12.70) and Dollar General (17.85). The Zacks Consensus Estimate for Costco's current financial-year sales and earnings per share implies year-over-year growth of 8.1% and 11.6%, respectively. Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Microsoft Stock Analysis: Buy or Sell?
Microsoft (NASDAQ: MSFT) reported spectacular quarterly financial results that pleased stock market investors. *Stock prices used were the afternoon prices of July 30, 2025. The video was published on August 1, 2025. Should you invest $1,000 in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
